Drugs / Nepicastat
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00656357 | Jun 2008 → May 2009 | cocaine dependence | Biotie Therapies Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00641511 | Jun 2008 → Sep 2009 | post-traumatic stress disorder | Michael E. DeBakey VA Medical Center | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01704196 Comparator | Apr 2013 → Aug 2014 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00659230 Comparator | Jul 2009 → Jul 2012 | post-traumatic stress disorder | Tuscaloosa Research & Education Advancement Corporation | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nepicastat | “A Human Laboratory Assessment of the Safety and Potential Efficacy of SYN117 (Nepicastat) in Cocaine-dependent Volunteers Receiving Cocaine” NCT00656357 ↗ |
| Known as | NEPICASTAT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1188395 ↗ |
| Known as | RS-25560-197 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1188395 ↗ |
| Known as | SYN117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00641511 ↗ |
| Action | Inhibit | “decrease neuronal noradrenaline (NA) release by inhibiting DBH conversion of dopamine (DA) to NA” NCT00659230 ↗ |
| Modality | Small molecule | — CHEMBL1188395 ↗ |
| Route | Oral | “120 mg on day 3 (orally)” NCT00641511 ↗ |
| Target | DBH | “inhibiting DBH conversion of dopamine (DA) to NA” NCT00659230 ↗ |